1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceutical Industry in Mexico

Pharmaceutical Industry in Mexico

  • January 2014
  • -
  • Aruvian's R'search
  • -
  • 160 pages

Mexico’s pharmaceutical policy environment is in a period of rapid evolution, with simultaneous policy development, refinement and ongoing implementation. This handicaps Mexico’s efforts to achieve policy goals efficiently at the present time, and also makes policy assessment and even accurate description difficult.

Mexico, along with almost all OECD countries, has witnessed growth rates in health expenditures that have surpassed general rates of inflation and, as in many cases, a main driver has been spending on pharmaceuticals. Like most OECD countries, annual growth in pharmaceutical expenditures in Mexico was greater than that for total health spending (net of pharmaceutical spending).

Aruvian Research brings you a complete analysis of the Pharmaceutical Industry in Mexico. The report covers a brief profile of the global pharmaceutical industry, the trends in the industry, competition in the industry, and key trends in the pharmaceutical supply chain in Mexico. The report also looks at strategies for market entry, the role of R&D in the Mexican Pharmaceutical Industry, and the role of the government in the industry.

Complete with a comprehensive section on the clinical trials, market investment opportunities going on in the Mexican pharmaceutical industry, Aruvians’ latest research is a collection of all you need to know about Mexico’s Pharmaceutical Industry.

Table Of Contents

Pharmaceutical Industry in Mexico
A. Executive Summary

B. Global Pharmaceutical Industry - A Brief Profile
B.1 Industry Definition
B.2 Industry Overview
B.3 Competition in the Global Pharmaceutical Industry
B.4 Industry Forecast

C. Mexico's Pharmaceutical Industry
C.1 Industry Overview
C.2 Industry Value
C.3 Market Segments
C.4 Market Share Analysis
C.5 Competition in the Industry
C.6 Pharmaceutical Expenditure
C.7 Industry Activity
C.8 Distribution Channels
C.9 RandD in the Industry
C.10 Clinical Trials
C.11 Emergence of Pharmacogenomics
C.12 Pharmaceutical Supply Chain
C.13 Demand Scenario for Pharmaceuticals
C.14 Import/Export Scenario

D. Mexico's OTC Pharmaceutical Sector
D.1 Sector Definition
D.2 Industry Overview
D.3 Industry Value
D.4 Market Segments
D.5 Market Share
D.6 Competition in the Industry
D.7 Distribution Channels
D.8 Sector Forecast

E. Pharmaceutical Pricing and Reimbursement in Mexico
E.1 Mexico's Regulatory Environment
E.2 Intellectual Property Rights
E.3 Product Approval Process
E.4 Pricing Policies
E.5 Coverage Scheme for Pharmaceuticals
E.6 Purchasing of Pharmaceuticals
E.7 Initiatives Influencing Pharmaceutical Consumption

F. Industry Forecast

G. Major Players
G.1 Abbott Laboratories
G.1.1 Corporate Profile
G.1.2 Business Segment Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Bayer AG
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 Boehringer Ingelheim GmbH
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis
G.4 Eli Lilly and Co
G.4.1 Corporate Profile
G.4.2 Business Segment Analysis
G.4.3 Financial Analysis
G.4.4 SWOT Analysis
G.5 GlaxoSmithKline Plc
G.5.1 Corporate Profile
G.5.2 Business Segment Analysis
G.5.3 Financial Analysis
G.5.4 SWOT Analysis
G.6 Johnson and Johnson
G.6.1 Corporate Profile
G.6.2 Business Segment Analysis
G.6.3 Financial Analysis
G.6.4 SWOT Analysis
G.7 Koninklijke DSM N.V.
G.7.1 Corporate Profile
G.7.2 Business Segment Analysis
G.7.3 Financial Analysis
G.7.4 SWOT Analysis
G.8 Pfizer
G.8.1 Corporate Profile
G.8.2 Business Segment Analysis
G.8.3 Financial Analysis
G.8.4 SWOT Analysis

H. Glossary of Terms



List of Figures

Figure 1: Geographic Segmentation of the Mexican Pharmaceutical Industry (%), 2012
Figure 2: Major Players in the Mexican Pharmaceutical Industry and their Market Share (%), 2012
Figure 3: Value of the OTC Market in Mexico (in USD Million), 2008-2012
Figure 4: Mexico OTC Market Segmentation (%), 2012
Figure 5: Share of Mexico's OTC Market in the Americas (%), 2012
Figure 6: Market Share of the Mexico OTC Industry (%), 2012
Figure 7: Share of the Mexican OTC Market by Distribution Channels (%), 2012
Figure 8: Forecast for the Mexican OTC Market (in USD Million), 2013-2017



List of Tables

Table 1: Mexican Pharmaceutical Industry Value (in USD Billion), 2008-2012
Table 2: Value of the OTC Market in Mexico (in USD Million), 2008-2012
Table 3: Mexico OTC Pharmaceuticals Market Segmentation, Value in USD Million and %, 2012
Table 4: Share of Mexico OTC Market in the Americas (in USD Million and %), 2012
Table 5: Forecast for the Mexican OTC Market (in USD Million), 2013-2017




Companies Mentioned

Abbott Laboratories
Bayer AG
Boehringer Ingelheim GmbH
Eli Lilly and Co
GlaxoSmithKline Plc
Johnson and Johnson
Koninklijke DSM N.V.
Pfizer

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Summary Melanoma is a type of cancer that begins in the ...

North America Vision Care Market Outlook to 2022

North America Vision Care Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

North America Vision Care Market Outlook to 2022 Summary GlobalData’s new report, "North America Vision Care Market Outlook to 2022", provides key market data on the North America Vision Care market. ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.